- Stocks
- Healthcare
- NASDAQ: AMGN

Price (delayed)

$211.8

Market cap

$120.27B

P/E Ratio

21.39

Dividend/share

$6.88

EPS

$9.9

Enterprise value

$146.42B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

The revenue has grown by 4.9% year-on-year

The debt has declined by 4.2% year-on-year

The P/E is 13% below the 5-year quarterly average of 24.8 but 2.5% above the last 4 quarters average of 21.0

AMGN's quick ratio is down by 46% year-on-year and by 26% since the previous quarter

Amgen's equity has decreased by 23% YoY and by 12% from the previous quarter

What are the main financial stats of AMGN

Market
Valuations
Earnings

Shares outstanding

567.85M

Market cap

$120.27B

Enterprise value

$146.42B

Price to earnings (P/E)

21.39

Price to book (P/B)

14.76

Price to sales (P/S)

4.76

EV/EBIT

19.06

EV/EBITDA

13.13

EV/Sales

5.75

Revenue

$25.48B

EBIT

$7.68B

EBITDA

$11.15B

Free cash flow

$8.9B

Per share
Balance sheet
Liquidity

EPS

$9.9

Free cash flow per share

$15.53

Book value per share

$14.35

Revenue per share

$44.47

TBVPS

$51.99

Total assets

$59.77B

Total liabilities

$51.53B

Debt

$32.78B

Equity

$8.25B

Working capital

$4.51B

Debt to equity

3.98

Current ratio

1.31

Quick ratio

0.86

Net debt/EBITDA

2.34

Margins
Efficiency
Dividend

EBITDA margin

43.8%

Gross margin

75.3%

Net margin

22.5%

Operating margin

29.1%

Return on assets

9.2%

Return on equity

60.6%

Return on invested capital

16.9%

Return on capital employed

17%

Return on sales

30.2%

Dividend yield

3.25%

DPS

$6.88

Payout ratio

69.5%

How has the Amgen stock price performed over time

Intraday

-0.61%

1 week

-1.65%

1 month

-4.93%

1 year

-14.26%

YTD

-7.88%

QTD

-13.11%

How have Amgen's revenue and profit performed over time

Revenue

$25.48B

Gross profit

$19.2B

Operating income

$7.42B

Net income

$5.75B

Gross margin

75.3%

Net margin

22.5%

The net margin has declined by 25% year-on-year and by 20% since the previous quarter

The company's operating margin fell by 23% YoY and by 18% QoQ

The net income has contracted by 21% YoY and by 19% from the previous quarter

AMGN's operating income is down by 19% year-on-year and by 17% since the previous quarter

What is Amgen's growth rate over time

What is Amgen stock price valuation

P/E

21.39

P/B

14.76

P/S

4.76

EV/EBIT

19.06

EV/EBITDA

13.13

EV/Sales

5.75

AMGN's EPS is down by 20% year-on-year and by 19% since the previous quarter

The P/E is 13% below the 5-year quarterly average of 24.8 but 2.5% above the last 4 quarters average of 21.0

The stock's price to book (P/B) is 55% more than its 5-year quarterly average of 9.6

Amgen's equity has decreased by 23% YoY and by 12% from the previous quarter

The P/S is 14% less than the last 4 quarters average of 5.6 and 11% less than the 5-year quarterly average of 5.4

The revenue has grown by 4.9% year-on-year

How efficient is Amgen business performance

The ROIC has contracted by 25% YoY and by 14% from the previous quarter

AMGN's return on assets is down by 23% year-on-year and by 17% since the previous quarter

AMGN's return on sales is down by 23% year-on-year and by 17% since the previous quarter

The ROE has contracted by 15% YoY and by 14% from the previous quarter

What is AMGN's dividend history

DPS

$6.88

Dividend yield

3.25%

Payout ratio

69.5%

Recent dividends

How did Amgen financials performed over time

Amgen's total assets is 16% more than its total liabilities

AMGN's quick ratio is down by 46% year-on-year and by 26% since the previous quarter

Amgen's current ratio has decreased by 40% YoY and by 21% from the previous quarter

AMGN's debt to equity is up by 24% YoY and by 14% QoQ

Amgen's equity has decreased by 23% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.